Latest Duchenne muscular dystrophy Stories
AMSTERDAM, May 19, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive.
DETROIT, April 25, 2011 /PRNewswire/ -- Cadillac and Sony Music are auctioning a Justin Bieber prize package to benefit Cure Duchenne, a nonprofit group that funds research and awareness of Duchenne, the most common muscle disease in children.
Researchers have long questioned why patients with Duchenne muscular dystrophy (DMD) tend to manage well through childhood and adolescence, yet succumb to their disease in early adulthood, or why elderly people who lose muscle strength following bed rest find it difficult or impossible to regain.
Grant Funds Work of Ronald G. Victor, M.D.
Zebrafish study highlights existing drugs that may help restore muscle in DMD BOSTON, March 18, 2011 /PRNewswire-USNewswire/ -- Armed with a zebrafish model of Duchenne muscular dystrophy (DMD) and a library of 1,200 chemicals already approved for human use, researchers at Children's Hospital Boston have identified a compound that reverses the loss of muscle structure and function associated with DMD, seemingly by compensating for the loss of a critical protein.
A strong international collaboration and a single patient with mild muscle disease and severe cognitive impairment have allowed University of Iowa researchers to identify a new gene mutation that causes muscular dystrophy.
AMSTERDAM, March 7, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (AMT) (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Duchenne Parent Project, based in the Netherlands, has awarded AMT a grant of EUR 145,000 to support the development of AMT-080, AMT's gene therapy for Duchenne Muscular Dystrophy (DMD).
Efforts over decade result in $192 million in Duchenne-specific federal investment HACKENSACK, N.J., Feb.
It's a gene called DOT1L, and if you donâ€™t have enough of the DOT1L enzyme, you could be at risk for some types of heart disease.
SOUTH PLAINFIELD, N.J. and HACKENSACK, N.J., Feb. 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) and Parent Project Muscular Dystrophy (PPMD) today announced an expansion of their collaboration to discover new treatments for patients with Duchenne/Becker muscular dystrophy (DBMD).
- a meat pie that is usually eaten at Christmas in Quebec